Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
about
Optimal usage of the GnRH antagonists: a review of the literatureGonadotrophin-releasing hormone antagonists for assisted reproductive technologyGonadotrophin-releasing hormone antagonists for assisted reproductive technologyGonadotrophin-releasing hormone antagonists for assisted conceptionDifferent ovarian stimulation protocols for women with diminished ovarian reserveThe role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and preventionGnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphologyComparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: A systematic review and meta-analysisThe effect of aromatase inhibitor letrozole incorporated in gonadotrophin-releasing hormone antagonist multiple dose protocol in poor responders undergoing in vitro fertilization.The Impact of Pituitary Blockage with GnRH Antagonist and Gonadotrophin Stimulation Length on The Outcome of ICSI Cycles in Women Older than 36 YearsSerum Oestradiol Pattern during Coasting is Different in Antagonist Cycles Compared with Long Agonist Cycles in In Vitro FertilisationParacrine/autocrine control of female reproduction.Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis.Outcome of cryopreserved-thawed embryo transfer in the GnRH agonist versus antagonist protocolEmbryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists.Gonadotropin-releasing hormone antagonists implications for oocyte quality and uterine receptivity.Cetrorelix in the treatment of female infertility and endometriosis.Cessation of gonadotropin-releasing hormone antagonist on triggering day: an alternative method for flexible multiple-dose protocolAssessment of the luteal phase in stimulated and substituted cycles.Clinical use of GnRH analogues.GnRH antagonists in the treatment of infertility.GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in Iran.GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET).Balancing selected medication costs with total number of daily injections: a preference analysis of GnRH-agonist and antagonist protocols by IVF patientsGn-RH antagonists in intrauterine insemination: the weekend-free protocolLuteal phase oestradiol administration in ovarian stimulation cycles with GnRH antagonist is comparable to the GnRH agonist (long) protocolApplication of GnRH antagonist in combination with clomiphene citrate and hMG for patients with exaggerated ovarian response in previous IVF/ICSI cycles.The effects of GnRH antagonist on the endometrium of normally menstruating women.GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol.Outcome of frozen-thawed blastocysts derived from gonadotropin releasing hormone agonist or antagonist cycles.Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis.Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multiple-dose protocol: A randomized controlled study.The effectiveness of earlier oocyte retrieval in the case of a premature luteinizing hormone surge on hCG day in in vitro fertilization-embryo transfer cycles.Impact of GnRH ovarian stimulation protocols on intracytoplasmic sperm injection outcomes.Does premature luteinization or early surge of LH impair cycle outcome? Report of two successful outcomesComparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles.Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment.Impact of GnRH analogues on oocyte/embryo quality and embryo development in in vitro fertilization/intracytoplasmic sperm injection cycles: a case control study.GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
P2860
Q21245566-1E001CF1-E525-4495-962D-14EA192009AAQ24185849-CB1265C5-FD69-47F2-ABBB-333EC1415B8BQ24234608-303B6A3D-6288-4ACB-801A-968BECE1568DQ24245006-FC211799-A74F-451A-88DF-A6E6C9621442Q24634342-1E5C16F7-98EF-4495-BEB7-58122CE7A2B5Q24816913-E9FF4546-FA65-4761-AE2B-05D1FED52E22Q26827593-FB0AFF53-C14B-44E1-817F-D4848A62912EQ31060385-D43C0ED2-8C2A-42CD-A154-63A9C9F4711CQ33596777-F92DF655-A137-40AB-86D6-C45AC2BB181DQ33686491-C2792BDA-79E6-4E27-904B-E19560845D65Q33937249-0F80F244-0BCB-4684-9145-30DC49C98FA4Q33974030-B0024BA6-00E4-474D-8469-E0C789CF1D3AQ34167840-748C2163-CBD2-4C72-B5F3-0C52C00DE952Q34172380-B67F826D-6CF5-4A73-B6CD-E8694DBAD639Q34196524-58E7292C-3605-45C8-9133-21D93D40C96BQ34201717-922F06C1-6703-4DFD-BECB-17CEE39F8E78Q34397296-FE0C5487-26C1-49F3-86BF-BDF3A851BCF0Q34571550-3E9840EE-A617-4151-BBC0-CC7A5868188FQ34607007-8104DA1B-5176-403F-A2E2-AC5B5BFA1485Q34608208-65D7A00A-5F75-4949-A6FD-F83742C83700Q34693073-1E7B3B9D-E9A5-4A45-9E75-5FCB6A9F25F9Q35597631-8ACAC772-ECE4-4374-86A4-723546FB069EQ36074736-6121558E-4270-44EB-8C6F-C6F2CFCDF857Q36235804-727DE967-1730-4370-B2F2-88440497FC6BQ36249259-3459EE65-4082-400C-BD78-8841EBE1401DQ36268184-70C3CFB2-EFE7-429D-8A58-AB49890B5EAAQ36268361-C59FF38E-9E58-4B1F-BA25-90F55570F064Q36268373-5A82EDC3-E36A-4DE6-A3B2-39E9C22559F3Q36268633-699AF91F-F710-445B-8016-330D06147634Q36308688-79484D26-A9DC-4836-973D-62E05148AC89Q36423226-22F26BF0-F989-4E9E-893A-CB0F8DE57E46Q36571890-171D97D1-680F-4ED6-9E95-6B44FA9E4A66Q37022407-521E8F2F-7583-47FC-8ABC-55463CADEF02Q37022412-28669DBC-5858-483C-BE7F-277D5378C1E8Q37077680-B312A827-21E9-4AC7-8493-1985D69D0224Q37126405-B599BCCF-2364-41D8-8003-710ECF722E3AQ37138027-2DF5C8E1-1839-4328-9624-E021F6990E6AQ37372180-36BE1906-8326-43BB-B95C-DD69FF8CD900Q37389594-9500DCF4-903D-49F0-8A1D-FFF8E6A6312EQ37598922-93DB4FE9-E7F4-4DF1-A15C-A7C0190C1D98
P2860
Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Prospective, randomized, contr ...... n LH-RH agonist (triptorelin).
@en
Prospective, randomized, contr ...... n LH-RH agonist (triptorelin).
@nl
type
label
Prospective, randomized, contr ...... n LH-RH agonist (triptorelin).
@en
Prospective, randomized, contr ...... n LH-RH agonist (triptorelin).
@nl
prefLabel
Prospective, randomized, contr ...... n LH-RH agonist (triptorelin).
@en
Prospective, randomized, contr ...... n LH-RH agonist (triptorelin).
@nl
P2093
P1476
Prospective, randomized, contr ...... n LH-RH agonist (triptorelin).
@en
P2093
B Nicollet
F Olivennes
J Belaisch-Allart
J C Emperaire
P Bouchard
P304
P356
10.1016/S0015-0282(99)00524-5
P407
P577
2000-02-01T00:00:00Z